Evidence map›Paper›PMID 36015305›Full record

ReviewPharmaceutics2022

Alternative Antibiotics in Dentistry: Antimicrobial Peptides.

Alexandra Griffith, Akilah Mateen, Kenneth Markowitz, Steven R Singer, Carla Cugini, Emi Shimizu, Gregory R Wiedman, Vivek Kumar

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Managing Oral Health in the Context of Antimicrobial Resistance.International journal of environmental research and public health · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandra GriffithDepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
Akilah MateenDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, NJ 07079, USA.
Kenneth MarkowitzDepartment of Oral Biology, Rutgers School of Dental Medicine, Newark, NJ 07103, USA.
Steven R SingerDepartment of Diagnostic Sciences, Rutgers School of Dental Medicine, Newark, NJ 07103, USA.
Carla CuginiDepartment of Oral Biology, Rutgers School of Dental Medicine, Newark, NJ 07103, USA.ORCID 0000-0001-5321-0608
Emi ShimizuDepartment of Oral Biology, Rutgers School of Dental Medicine, Newark, NJ 07103, USA.
Gregory R WiedmanDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, NJ 07079, USA.ORCID 0000-0002-6720-699X
Vivek KumarDepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.ORCID 0000-0001-7536-9281

Funding

Diversity Supplement for Angiogenic and anti-microbial supports for pulp regenerationR01DE031812 · NIDCR · UNIVERSITY OF HOUSTON · PI Vivek Kumar · 2022 to 2026
$3.3M
Growth factors-induced dentinogenesisR01DE025885 · NIDCR · RBHS-SCHOOL OF DENTAL MEDICINE · PI SHIMIZU, EMI · 2016 to 2021
$2.1M
Peptide hydrogels for management and treatment of neovascular posterior segment diseasesR15EY029504 · NEI · NEW JERSEY INSTITUTE OF TECHNOLOGY · PI KUMAR, VIVEK · 2019 to 2020
$508k
Role of Dispersin B in the colonization and virulence of Aggregatibacter actinomycetemcomitansR21DE027125 · NIDCR · RBHS-SCHOOL OF DENTAL MEDICINE · PI CUGINI, CARLA, RAMASUBBU, NARAYANAN · 2018 to 2019
$437k
NEI NIH HHS EY029504NEI NIH HHS R15 EY029504NIDCR NIH HHS DE025885NIDCR NIH HHS DE027125NIDCR NIH HHS DE031812NIDCR NIH HHS R01 DE025885NIDCR NIH HHS R01 DE031812NIDCR NIH HHS R21 DE027125
6 · The paper itself

Abstract

The rise of antibiotic resistant bacteria due to overuse and misuse of antibiotics in medicine and dentistry is a growing concern. New approaches are needed to combat antibiotic resistant (AR) bacterial infections. There are a number of methods available and in development to address AR infections. Dentists conventionally use chemicals such as chlorohexidine and calcium hydroxide to kill oral bacteria, with many groups recently developing more biocompatible antimicrobial peptides (AMPs) for use in the oral cavity. AMPs are promising candidates in the treatment of (oral) infections. Also known as host defense peptides, AMPs have been isolated from animals across all kingdoms of life and play an integral role in the innate immunity of both prokaryotic and eukaryotic organisms by responding to pathogens. Despite progress over the last four decades, there are only a few AMPs approved for clinical use. This review summarizes an Introduction to Oral Microbiome and Oral Infections, Traditional Antibiotics and Alternatives & Antimicrobial Peptides. There is a focus on cationic AMP characteristics and mechanisms of actions, and an overview of animal-derived natural and synthetic AMPs, as well as observed microbial resistance.

Indexed as

AMPsantibiotic resistanceanti-microbial peptidesmicrobiomeoral infections

Identifiers

PMID36015305
PMCPMC9412702

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.